News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 672 results
June 2018
-
Media ReleaseNovartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCLOverall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable (1)Patients had a 65% chance of being relapse-free…
-
Media ReleaseNovartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
-
Media ReleaseNovartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life-- Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%)-- About two-thirds of…
-
Media ReleaseNovartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
-
Media ReleaseThird Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer- Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line…
-
Media ReleaseThird Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
May 2018
-
Media ReleaseFDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)- Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy…
-
Media ReleaseFDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
-
Media ReleasePatient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®- Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)1-…
-
Media ReleasePatient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
-
Media ReleaseNovartis and Amgen announce FDA approval of Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine prevention- Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States- Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-related…
-
Media ReleaseNovartis and Amgen announce FDA approval of Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine prevention
Pagination
- ‹ Previous page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- …
- 56
- › Next page